DocWire News Editors

DocwireNews

Seeking to answer if screening asymptomatic individuals for atrial fibrillation (AF) could offer meaningful protection against strokes and other clinical outcomes, Steven Steinhubl, MD, from the Scripps Research Translational Institute in La Jolla, CA, and other collaborators analyzed data from the mHealth Screening to Prevent Strokes (mSToPS) trial.&nbsp;They found that individuals actively screened for AF had a lower rate of clinical events over three years after electrocardiogram (ECG)-patch screening relative to routine care, though the impact of earlier AF detection via screening was not clear.&nbsp;The study report, published in PLoS One, argued that the observations made &ldquo;support the need for randomized trials to determine whether screening for AF will yield a meaningful protection from strokes and other clinical events.&rdquo;&nbsp;Participants in the mSToPS study were randomized to immediate or delayed screening groups with an ECG patch to detect possible undiagnosed instances of AF. Clinical outcomes were compared at three years in the study&rsquo;s cohort of 1,718 individuals who underwent active AF monitoring and 3,371 matched controls. The primary endpoint was the time to first event of the combined outcomes of death, stroke, systemic embolism, or myocardial infarction among individuals with a new AF diagnosis.&nbsp;AF was newly diagnosed in 11.4% (n = 196) of participants in the screening group versus 7.7% (n = 261) of the observational controls (P &lt;0.01). For all individuals diagnosed clinically, a clinical event was common in the four weeks surrounding that diagnosis: 6.6% experienced a stroke, 10.2% were newly diagnosed with heart failure, 9.2% had a myocardial infarction, and 1.5% had a systemic embolus.&nbsp;On the other hand, in the one-third of incident AF cases diagnosed through active ECG monitoring, no patients experienced stroke, myocardial infarction, or systemic emboli in the period surrounding their diagnosis, and only one had a new diagnosis of heart failure. The incidence of the primary endpoints was 3.6 per 100 person-years among the actively screened group and 4.5 per 100 person-years in the controls.&nbsp;The investigators did note their study was limited by the strong possibility of unmeasured confounders. Additionally, endpoints were based on claims and membership data which limited follow-up data if participants changed plans (less than three years in some participants). The authors also noted that approximately one-third of study participants never wore their ECG patch monitor, indicating a need for different real-world implementation.&nbsp;Despite the unclear effect of earlier diagnoses of AF via active screening on the clinical events and outcomes seen in the study, the researchers argued that their observations&mdash;particularly the heightened rate of events surrounding a clinical AF diagnosis&mdash;supported the &ldquo;need for randomized trials to determine whether screening for AF will yield a meaningful protection from strokes and other clinical events.&rdquo;&nbsp;

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

Active Screening for Atrial Fibrillation to Protect Against Strokes and Other Events

Atrial Fibrillation

Seeking to answer if screening asymptomatic individuals for atrial fibrillation (AF) could offer meaningful protection against strokes and other clinical outcomes, Steven ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe